Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study.

OBJECTIVE To analyze the influence of cyclosporine A (CYA) on bone using data from a large multicenter, cross-sectional study on bone mineral density (BMD) in rheumatoid arthritis (RA). METHODS We selected 558 female patients with RA and divided them into two groups on the basis of CYA use: those who had never used CYA (n = 467) and CYA users (n = 91; users for < 24 months n = 50; users for > 24 months n = 41). Demographic, disease and treatment-related variables were collected for each patient. BMD was measured at the lumbar spine and proximal femur using dual x-ray absorptiometry. Data was analyzed by means of a univariate and multivariate statistical procedure. Osteoporosis (OP) was defined as BMD < -2.5 T score. RESULTS The frequency of OP among non-CYA users and CYA users was 28.2% and 33.3% (p=NS) for the lumbar spine, and 34.2% and 31.3% (p=NS) for the femoral neck, respectively. The prevalence of fragility fractures was not significantly different between the two groups. Mean values for the T-score at either the lumbar spine or the femoral neck were comparable in the two groups, even after adjustment for age, menopausal status, body mass index (BMI), Health Assessment Questionnaire (HAQ) score and steroid use. The generalized linear model showed that age, BMI and the HAQ score were significant independent predictors of BMD at the lumbar and femoral levels, whereas CYA use was not. Logistic analysis showed that only age, the HAQ score and BMI were significantly associated with the risk of OP. However, the duration of CYA therapy > 24 months was associated with an adjusted decreased lumbar BMD and a significantly decreased femoral neck BMD (p = 0.01). The frequency of femoral neck OP in patients on CYA for > 24 months was significantly higher than in patients on CYA for < 24 months: 46.4% vs. 19.44% (p=0.03), while the prevalence of fragility fractures did not differ significantly: 23.1% vs. 16.6%, respectively (p=NS). Logistic analysis showed that CYA use was an independent predictor of osteoporosis at the femoral site. CONCLUSION Long-term CYA therapy may have negative effects on BMD in female RA patients.

[1]  S. Epstein,et al.  Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  E. Shane,et al.  Erratum: Clinical review: Osteoporosis after solid organ transplantation (The Journal of Clinical Endocrinology (2005) 90 (2456-2465)) , 2005 .

[3]  S. Adami,et al.  Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. , 2004, The Journal of rheumatology.

[4]  B. Riggs,et al.  Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. , 2001, Biochemical and biophysical research communications.

[5]  S. Adami,et al.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. , 2000, The Journal of rheumatology.

[6]  J. Achard,et al.  Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. , 2000, Kidney international.

[7]  G. Pasero,et al.  Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate. , 2000, Clinical and experimental rheumatology.

[8]  J. Adams,et al.  Bone loss in long-term renal transplantation: histopathology and densitometry analysis. , 1999, Kidney international.

[9]  J. Hopper,et al.  Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  P. Altmann,et al.  Long-term bone densitometry post-renal transplantation in patients treated with either cyclosporin or prednisolone. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  C. Ponticelli,et al.  Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. , 1997, Transplantation.

[12]  E. Bartoli,et al.  Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. , 1996, The Journal of rheumatology.

[13]  J. Goy,et al.  Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation , 1996, European journal of clinical investigation.

[14]  G. Pasero,et al.  Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. , 1996, Arthritis and rheumatism.

[15]  S. Epstein Post‐transplantation bone disease: The role of immunosuppressive agents and the skeleton , 1996 .

[16]  V. Briner,et al.  Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. , 1995, Transplantation.

[17]  C. Hawley,et al.  Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. , 1995, Clinical transplantation.

[18]  O. Førre Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. , 1994, Arthritis and rheumatism.

[19]  B. Dijkmans,et al.  A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[20]  S. Epstein,et al.  The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. , 1994, Transplantation.

[21]  S. Epstein,et al.  Influence of age on cyclosporin A‐induced alterations in bone mineral metabolism in the rat in vivo , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  E. Shane,et al.  Osteoporosis after cardiac transplantation. , 1993, The American journal of medicine.

[23]  P. Tugwell,et al.  Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis , 1990, The Lancet.

[24]  S. Epstein,et al.  Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. , 1988, Endocrinology.

[25]  A. Masi,et al.  Preliminary criteria for clinical remission in rheumatoid arthritis. , 1981, Arthritis and rheumatism.

[26]  O. Steinbrocker,et al.  Therapeutic criteria in rheumatoid arthritis. , 1949, Journal of the American Medical Association.